B+
Bull case
20%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
GPCR
Structure TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The company reported up to 16.2% weight loss at 72 weeks in the aleniglipron ACCESS open-label extension, with fewer than 5% discontinuing due to adverse events. Constructive Q4 results and repeat-dose ACCG-2671 data could strengthen the case for an oral obesity portfolio.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -44.1.
What can break
ACCG-2671 showed dose-related nausea and vomiting in higher-dose single-dose cohorts; repeat-dose tolerability is unproven. [#PR-2026-09-08]
Momentum
2
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $22.00 · Bull $34.00 · Bear $12.00Analysis 2026-10-21; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $106.73
Why
Momentum2 · Δ7d -0.1
Value41 · Δ7d -0.1
Sentiment54 · Δ7d -44.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -44.1.
Contradictions & invalidation
- • ACCG-2671 showed dose-related nausea and vomiting in higher-dose single-dose cohorts; repeat-dose tolerability is unproven. [#PR-2026-09-08]
- • Large commercial incumbents and other development-stage obesity programs create pricing, access, and efficacy competition.
- • The thesis depends on clinical translation and lengthy Phase 3 execution.
Catalyst clock
2026-11-15
Aleniglipron presentations at ObesityWeek
Lead driver: Sentiment · See AI snapshot
Momentum
2
8% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-1.2
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
54
45% active weight
Current posture
7d trendSoftening
Δ7d
-44.1
Δ21d
-32.7
Why this grade
Composite grade D. Momentum 2.0 / Value 40.6 / Sentiment 53.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-21. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.51B
Beta
-
Shares Out
71.31M
P/E (TTM) · Derived
-8.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.09
Rev YoY
-
EPS YoY
+36.1%
Gross Margin
-
Op Margin
-
Net Debt
-$1.44B
Current Ratio
20.75
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data